

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
	Applicant: David J. YANG <i>et al.</i>	
	Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A64	10/627,763	07/28/03	Lin			07/28/03
	A65	11/737,694	04/19/07	Yang			04/19/07
	A66	60/828,347	10/05/06	Yang			10/05/05
	A67	2003/0013772	01/06/03	Murphy <i>et al.</i>	514	674	12/18/01
	A68	2003/0152512	08/14/03	Rajopadhye <i>et al.</i>	424	1.49	11/13/01
	A69	2003/0206865	11/06/03	Platzek <i>et al.</i>	424	9.363	07/19/02
	A70	4,141,654	02/27/79	Wardlaw <i>et al.</i>	356	243.1	05/23/77
	A71	4,181,654	01/01/80	Weitl <i>et al.</i>	260	239	07/24/78
	A72	5,071,965	12/10/91	Dunn <i>et al.</i>	534	14	02/24/89
	A73	5,474,756	12/12/95	Tweedle <i>et al.</i>	424	9.363	12/20/94
	A74	5,541,287	07/30/96	Yau <i>et al.</i>	530	317	11/22/94
	A75	5,601,800	02/11/97	Katti <i>et al.</i>	424	1.77	11/09/92
	A76	5,605,672	02/25/97	Bogdanov <i>et al.</i>	424	1.65	06/09/93
	A77	5,608,060	05/04/97	Axworthy <i>et al.</i>	540	474	06/07/93
	A78	5,648,063	07/15/97	Gries <i>et al.</i>	424	9.363	08/04/93
	A79	5,674,470	10/07/97	Tweedle <i>et al.</i>	424	9.363	06/06/95
	A80	5,846,519	12/08/98	Tweedle <i>et al.</i>	424	9.363	06/06/95
	A81	5,847,121	12/08/98	Yau <i>et al.</i>	540	474	12/13/95
	A82	5,880,281	03/09/99	Argese <i>et al.</i>	540	474	06/19/97
	A83	5,955,605	09/21/99	Axworthy <i>et al.</i>	540	474	08/12/96
	A84	5,958,374	09/28/99	Meares <i>et al.</i>	424	1.65	12/17/96
	A85	6,071,490	06/06/00	Griffiths <i>et al.</i>	424	1.49	05/07/99
	A86	6,117,551	01/23/01	Kasina	534	10	05/12/99

55092434.1

EXAMINER: /Leah Schlientz/**DATE CONSIDERED:** 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A87	6,143,274	11/07/00	Tweedle <i>et al.</i>	424	1.65	06/06/95
	A88	6,187,286	02/13/01	Elmaleh <i>et al.</i>	424	1.73	05/01/97
	A89	6,232,295	05/15/01	Kayyem <i>et al.</i>	514	44	10/12/94
	A90	6,440,389	08/27/02	Rabito	424	009.6	08/02/00
	A91	6,521,209	02/18/03	Meade <i>et al.</i>	424	9.3	08/01/00
	A92	6,613,305	09/02/03	Collins <i>et al.</i>	424	1.73	07/26/00
	A93	6,656,450	12/02/03	Hubin <i>et al.</i>	424	9.363	07/17/01
	A94	6,713,046	03/30/04	Meade	424	9.363	10/27/98
	A95	6,737,247	05/18/04	Bogdanov <i>et al.</i>	435	25	10/19/01
	A96	7,067,111	06/27/06	Yang <i>et al.</i>	424	9.1	06/21/00
	A97	7,121,926	10/17/06	Sabde	451	41	12/21/01
	A98	7,223,380	05/29/07	Yang <i>et al.</i>	424	9.4	09/26/03
	A99	7,229,604	06/12/07	Yang <i>et al.</i>	424	9.1	10/26/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B12	EP 1156091	11/21/01	Europe	German
	B13	WO 99/56792	10/31/91	PCT	English
	B14	WO 00/45857	08/10/00	PCT	German (English Abstract)
	B15	WO 02/06209	01/24/02	PCT	French (English Abstract)
	B16	WO 02/43775	06/06/02	PCT	English
	B17	WO 03/009874	02/06/03	PCT	German (English Abstract)
	B18	WO 03/051403	06/26/03	PCT	English

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B19	WO 06/016784	05/04/06	PCT	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C376	Aime <i>et al.</i> , "Ternary Gd(III)L-HAS adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. implications for the design of contrast agents for MRI," <i>J. of Biol. Inorg. Chem.</i> , 5:488-497, 2000.
	C377	Angello <i>et al.</i> , "Effect of eating on thallium-201 myocardial redistribution after myocardial ischemia," <i>Am. J. Cardiol.</i> , 60:528-533, 1987.
	C378	Benveniste and Davies, "Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria," <i>Proc. Natl. Acad. Sci. USA</i> , 70:2276-2280, 1973.
	C379	Borchardt <i>et al.</i> , "Targeted actinium-225 in vivo generators for therapy of ovarian cancer," <i>Cancer Research</i> , 63:5084-5090, 2003.
	C380	Borodina <i>et al.</i> , "Metabolic network analysis of <i>Streptomyces tenebrarius</i> , a <i>Streptomyces</i> species with an active entner-doudoroff pathway," <i>Appl. Environ. Microb.</i> , 71:2294-2302, 2005.
	C381	Boschi <i>et al.</i> , "A CD(4)/T(4) receptor peptide ligand labeled with technetium-99m: synthesis and biological activity," <i>Nucl. Med. Biol.</i> , 27:791-795, 2000.
	C382	Botta <i>et al.</i> , "NMR relaxometric study of new Gd ^{III} macrocyclic complexes and their interaction with human serum albumin," <i>Organic & Biomolecular Chemistry</i> , 2:570-577, 2004
	C383	Brouwers <i>et al.</i> , "Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with ¹³¹ I, ⁹⁰ I, ¹⁷⁷ Lu, or ¹⁸⁶ Re," <i>J. Nucl. Med.</i> , 45:327-337, 2004.
	C384	Canet <i>et al.</i> , "Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI," <i>Magnetic Resonance in Medicine</i> , 43:403-409, 2000.
	C385	Chappell <i>et al.</i> , "Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes ²⁰³ Pb and ²¹² Pb," <i>Nucl. Med. Biol.</i> , 27:93-100, 2000.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C386	Chmura <i>et al.</i> , "Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies," <i>J. of Controlled Release</i> , 78:249-258, 2002.
	C387	Connett <i>et al.</i> , "Maximum tolerated dose and large tumor radioimmunotherapy studies of ⁶⁴ Cu-labeled monoclonal antibody 1A3 in a colon cancer model," <i>Clin. Cancer Res.</i> , 5(10 Suppl):3207s-3212s, 1999.
	C388	Connett <i>et al.</i> , "Radioimmunotherapy with a ⁶⁴ Cu-labeled monoclonal antibody: a comparison with ⁶⁷ Cu," <i>Proc. Natl. Acad. Sci. USA</i> , 93:6814-6818, 1996.
	C389	Craig <i>et al.</i> , "Renal outcomes for children on year after urinary tract infection," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 175, 1996.
	C390	Cronin <i>et al.</i> , "A new class of macrocycle capable of binding exogenous metals: synthesis, structure, magnetic and electrochemical properties of a Cu(II) trinuclear complex based upon 1,4,8,11-tetraazacyclotetradecane-2,3-dione [exoO(2)]cyclam," <i>J. Chem. Soc., Dalton Transactions</i> , 12:1925-1927, 1999.
	C391	Cutler <i>et al.</i> , "Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso," <i>J. Nucl. Med.</i> , 36:2363-2371, 1995.
	C392	Das <i>et al.</i> , "[^{186/188} Re] rhenium-ethylene dicysteine (Re-Ec): preparation and evaluation for possible use in endovascular brachytherapy," <i>Nucl. Med. Biol.</i> , 27:189-197, 2000.
	C393	DeNardo <i>et al.</i> , "Enhancement of ⁶⁷ Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2," <i>Cancer</i> , 80(12 Suppl):2576-2582, 1997.
	C394	Diamond <i>et al.</i> , "Glycolysis in quiescent cultures of 3T3 cells. Stimulation by serum, epidermal growth factor, and insulin in intact cells and persistence of the stimulation after cell homogenization," <i>J. Biol. Chem.</i> , 253:866-871, 1978.
	C395	Drapé <i>et al.</i> , "Intraarticular diffusion of Gd-DOTA after intravenous injection in the knee: MR imaging evaluation," <i>Radiology</i> , 188:227-234, 1993.
	C396	Edreira <i>et al.</i> , "Optimization of the small-scale synthesis of DOTA-Tyr ³ -octreotide," <i>Nuclear Medicine Communications</i> , 23:493-499, 2002.
	C397	Ellis and Sharma, "Co, Fe and Ga chelates for cell labelling: a potential use in PET imaging?" <i>Nuclear Medicine Communications</i> , 20:1017-1021, 1999.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C398	Froidevaux <i>et al.</i> , "Preclinical comparison in AR4-2J tumor bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid somatostatin analogs for tumor diagnosis and internal radiotherapy," <i>Endocrinology</i> , 141:3304-3312, 2000.
	C399	Green and Wuts, Chapter 1, 1999.
	C400	Green and Wuts, Chapter 2, 1999.
	C401	Green and Wuts, Chapter 4, 1999.
	C402	Green and Wuts, Chapter 5, 1999.
	C403	Green and Wuts, Chapter 6, 1999.
	C404	Green and Wuts, Chapter 7, 1999.
	C405	Gregson <i>et al.</i> , "meso-5,5,7,12,14-Hexamethyl-1,4,8,11-tetraazacyclotetradecane as a building block in supramolecular chemistry; salts formed with 2,2'-biphenol, 4,4'-thiodiphenol, 4,4'-sulfonyldiphenol, 3-and 4-hydroxybenzoic acids, 3,5-dihydroxybenzoic acid and phenylphosphonic acid; supramolecular structures in zero, one, two and three dimensions," <i>Acta Crystallogr.</i> , B56:39-57, 2000.
	C406	Griffiths <i>et al.</i> , " ⁹⁰ Y-DOTA-hLL2: an agent for radioimmunotherapy of Non-Hodgkin's lymphoma," <i>J. Nucl. Med.</i> , 44:77-84, 2003.
	C407	Gutman <i>et al.</i> , Time to completed redistribution of thallium-201 in exercise myocardial scintigraphy: relationship to the degree of coronary artery stenosis," <i>Am. Heart J.</i> , 106:989-995, 1983.
	C408	Henson <i>et al.</i> , "Gadolinium-enhanced CT angiography of the circle of Willis and neck," <i>AJNR Am. J. Neuroradiol.</i> , 25:969-972, 2004.
	C409	Hoelscher <i>et al.</i> , "Effects of very high antibiotic concentrations on human intervertebral disc cell proliferation, viability, and metabolism in vitro," <i>Spine</i> , 25:1871-1877, 2000.
	C410	Honess <i>et al.</i> , "Preclinical evaluation of the novel hypoxic marker ^{99m} Tc-HL91 (prognox) in murine and xenograft systems in vivo," <i>Int. J. Radiation Oncology Biol. Phys.</i> , 42:731-735, 1998.
	C411	Hostetler and Hall, "Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity," <i>PNAS</i> , 79:1663-1667, 1982.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER:

/Leah Schlientz/

DATE CONSIDERED:

09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C412	Hu, "Neomycin inhibits angiogenin-induced angiogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , 95:9791-9795, 1998.
	C413	Im <i>et al.</i> , "Formation, properties, and characterization of a fully reduced Fe(II)Fe(II) form of spinach (and parsley) [2Fe-2S] ferredoxin with the macrocyclic complex [Cr(15-aneN(4))(H(2)O)(2)](2+) as reductant," <i>Inorg. Chem.</i> , 36:1388-1396, 1997.
	C414	Im <i>et al.</i> , "The Cr ^{II} L reduction of [2Fe-2S] ferredoxins and site of attachment of Cr ^{III} using ¹ H NMR and site-directed mutagenesis," <i>Inorg. Chem.</i> , 39:1755-1764, 2000.
	C415	Ito <i>et al.</i> , "PET and planar imaging of tumor hypoxia with labeled metronidazole," <i>Acad. Radiol.</i> , 13:598-609, 2006.
	C416	Kao <i>et al.</i> , "Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma," <i>Cancer</i> , 83:64-68, 1998
	C417	King <i>et al.</i> , "Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging," <i>European Journal of Nuclear Medicine</i> , 17:18-151, 1990.
	C418	Kitamura and Shibata, "Preparation and the covalent hydration of a hexafluoro-2,4-pentanedionatotetraamincobalt(III) complex," <i>Inorganica Chimica Acta</i> , 203:37-42, 1993.
	C419	Knight <i>et al.</i> , "Radiolabeling of fibrinogen using the lodogen technique," <i>Throm. Res. Cen. Dept. Biochem.</i> , pp 593-596, 1982.
	C420	Kundra <i>et al.</i> , "Noninvasive monitoring of somatostatin receptor type 2 chimeric gene transfer," <i>J. Nucl. Med.</i> , 43:406-412, 2002.
	C421	Laissy <i>et al.</i> , "Functional evaluation of normal and ischemic kidney by means of gadolinium-DOTA enhanced TurboFLASH MR imaging: a preliminary comparison with 99Tc-MAG3 dynamic scintigraphy," <i>Magn. Reson. Imaging</i> , 12:413-419, 1994.
	C422	Lewis <i>et al.</i> , "Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3," <i>Cancer Biother. Radiopharm.</i> , 16:483-94, 2001.
	C423	Li <i>et al.</i> , "N,N'-Ethylenedi-L-cysteine (EC) and its metal complexes: synthesis, characterization, crystal structures, and equilibrium constants," <i>Inorg. Chem.</i> , 35:404-414, 1996

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C424	Li <i>et al.</i> , "Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions," <i>Bioconjugate Chem.</i> , 13:110-115, 2002.
	C425	Luckay <i>et al.</i> , "Synthesis and structure of a complex of bismuth(III) with nitrogen donor macrocycle," <i>Journal of the Chemical Society, Chem. Comm.</i> , 2365-2366, 1995.
	C426	Michalik <i>et al.</i> , "Effect of various aminoglycoside antibiotics on glucose formation in isolated rabbit kidney-cortex tubules," <i>Pharmacol. Res.</i> , 21:405-414, 1989.
	C427	Murakami <i>et al.</i> , "Calcium hydroxide ameliorates tobramycin toxicity in cultured chick tibiae," <i>Bone</i> , 21:411-418, 1997.
	C428	Murakami <i>et al.</i> , "Interaction of tobramycin and pH in cultured chick tibiae," <i>J. Orthop. Res.</i> , 14:742-748, 1996.
	C429	Myszka <i>et al.</i> , "Synthesis and induction of apoptosis in B cell chronic leukemia by diosgenyl 2-amino-2-deoxy-beta-D-glucopyranoside hydrochloride and its derivatives," <i>Carb. Res.</i> , 338:133-141, 2003.
	C430	Nakae and Nakae, "Diffusion of aminoglycoside antibiotics across the outer membrane of <i>Escherichia coli</i> ," <i>Antimicrobial Agents and Chemo.</i> , 22:554-559, 1982.
	C431	Ohtsuki <i>et al.</i> , "Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis," <i>Eur. J. Nucl. Med.</i> , 26:1251-1258, 1999.
	C432	Ozmen <i>et al.</i> , "Effects of some antibiotics on activity of glucose-6-phosphate dehydrogenase from human erythrocytes in vitro and effect of isepamicin sulfate on activities of antioxidant enzymes in rat erythrocytes," <i>Drug Chem. Toxicol.</i> , 28:433-445, 2005.
	C433	Panneerselvam <i>et al.</i> , "(12-hydroxymethyl-5,5,7,12,14-pentamethyl-1,4,8,11-tetraazacyclo-tetradecane-N-acetato-N,N',N'',N''';O,O')cobalt(III) chloride perchlorate monohydrate," <i>Acta Crystallogr., C</i> 56:659-660, 2000.
	C434	Philpott <i>et al.</i> , "RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody," <i>J. Nucl. Med.</i> , 36:1818-1824, 1995.
	C435	Pohost <i>et al.</i> , "Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201," <i>Circulation</i> , 55:294-302, 1977.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C436	Ranganathan <i>et al.</i> , "Polymethylated DOTA ligands. 2. synthesis of rigidified lanthanide chelates and studies on the effect of alkyl substitution on conformational mobility and relaxivity," <i>Inorg. Chem.</i> , 41:6856-6866, 2002.
	C437	Ruegg <i>et al.</i> , "Improved <i>in vivo</i> stability and tumor targeting of bismuth-labeled antibody," <i>Cancer research</i> , 50:4221-4226, 1990.
	C438	Schechter <i>et al.</i> , "Assessment of epidermal growth factor receptor with 99mTc-ethylenedicycysteine-C225 monoclonal antibody," <i>Anticancer Drugs</i> , 14:49-56, 2003.
	C439	Schechter <i>et al.</i> , "Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck," <i>J. Nucl. Med.</i> , 45:1683-1687.
	C440	Sharkey <i>et al.</i> , "Radioimmunotherapy of Non-Hodgkin's lymphoma with ⁹⁰ Y-DOTA humanized anti-CD22 IgG (⁹⁰ Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?" <i>J. Nucl. Med.</i> , 44:2000-2018, 2003.
	C441	Silverman <i>et al.</i> , "Evaluating tumor biology and oncological disease with positron-emission tomography," <i>Seminars in Radiation Oncology</i> , 8:183-196, 1998.
	C442	Smith <i>et al.</i> , "Radiochemical investigations of ¹⁷⁷ Lu-DOTA-8-Aoc-BBN[7-14]NH ₂ : an <i>in vitro/in vivo</i> assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells," <i>Nuclear Medicine and Biol.</i> , 30:101-109, 2003.
	C443	Song <i>et al.</i> , "Prognostication of recovery in patients with acute ischemic stroke through the use of brain SPECT with Technetium-99m--labeled metronidazole," <i>Stroke</i> , 34:982-986, 2003.
	C444	Srivastava <i>et al.</i> , "Comparative evaluation of chelating agents on the mobilization of cadmium: a mechanistic approach," <i>J. Toxicology and Environmental Health</i> , 47:173-182, 1996.
	C445	Stein <i>et al.</i> , "Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of ¹⁷⁷ Lu and comparison of its efficacy with that of ⁹⁰ Y and residualizing ¹³¹ I," <i>J. Nucl. Med.</i> , 42:967-974, 2001.
	C446	Tachibana <i>et al.</i> , "Inhibitory effects of kanamycin on glycolysis in cochlea and kidney-possible involvement in the formation of oto- and nephrotoxicities," <i>Biochem. Pharmacol.</i> , 25:2297-2301, 1976.
	C447	Tod <i>et al.</i> , "Clinical pharmacokinetics and pharmacodynamics of isepamicin," <i>Clin. Pharmacokinet.</i> , 38:205-223, 2000.

55092434.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C448	Vogler <i>et al.</i> , "Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging," <i>Eur. J. Radiol.</i> , 21:1-10, 1995.
	C449	Vriens <i>et al.</i> , "The use of technetium ^{99m} Tc annexin V for in vivo imaging of apoptosis during cardiac allograft rejection," <i>J. Thorac. Cardiovasc. Surg.</i> , 116:844-853, 1998.
	C450	Wang <i>et al.</i> , "[Cu(L)Mn(N ₃) ₂] _n : the first complex containing both macrocyclic oxamido and alternate (mu-1,1 and mu-1,3) azido bridges," <i>Inorg. Chem.</i> , 43:852-854, 2004.
	C451	Wester <i>et al.</i> , "Synthesis and radiopharmacology of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine for tumor imaging," <i>J. Nucl. Med.</i> , 40:205-212, 1999.
	C452	Wu <i>et al.</i> , "High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," <i>Proc. Nat. Acad. Sci. USA</i> , 97:8495-8500, 2000.
	C453	Wu <i>et al.</i> , "Investigations of N-linked macrocycles for ¹¹¹ In and ⁹⁰ Y labeling of proteins," <i>Nucl. Med. & Biol.</i> , 19:239-244, 1992.
	C454	Wu <i>et al.</i> , "Using Tc-99m DMSA renal cortex scan to detect renal damage in women with type 2 diabetes," <i>J. Diabetes Complications</i> , 17:297-300, 2003.
	C455	Yanai <i>et al.</i> , "Amplification of the entire kanamycin biosynthetic gene cluster during empirical strain improvement of <i>Streptomyces kanamyceticus</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 103:9661-9666, 2006.
	C456	Yang and Kim, "Tracer development and hybrid imaging," <i>Eur. J. Nucl. Med. Mol. Imaging</i> , 32:1001-1002, 2005.
	C457	Yang <i>et al.</i> , "(^{99m} Tc)-EC-guanine: synthesis, biodistribution, and tumor imaging in animals," <i>Pharm. Res.</i> , 22:1471-1479, 2005.
	C458	Yang <i>et al.</i> , "Assessment of antiangiogenic effect using ^{99m} Tc-EC-endostatin," <i>Cancer Biother. Radiopharm.</i> , 17:233-245, 2002.
	C459	Yang <i>et al.</i> , "Assessment of cyclooxygenase-2 expression with ^{99m} Tc-labeled celebrex," <i>Anticancer drugs</i> , 15:255-263, 2004.
	C460	Yang <i>et al.</i> , "Imaging with ^{99m} Tc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents," <i>Radiology</i> , 226:465-473, 2003.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:841US	Serial No.: 10/732,919
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: David J. YANG <i>et al.</i>	
		Filing Date: December 10, 2003	Group: 1618
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C461	Yang <i>et al.</i> , "In vivo and in vitro measurement of apoptosis in breast cancer cells using (99m)Tc-EC-annexin V," <i>Cancer Biotherapy</i> , 16:73-83, 2001.
	C462	Yang <i>et al.</i> , "Metabolic pathways that mediate inhibition of hypothalamic neurons by glucose," <i>Diabetes</i> , 53:67-73, 2004.
	C463	Yang <i>et al.</i> , "Targeted molecular imaging in oncology," <i>Ann. Nucl. Med.</i> , 20:1-11, 2006.
	C464	Zhang <i>et al.</i> , "A ferromagnetically coupled CrCu ₃ tetramer and GdCu ₄ pentamer with a [15]N ₄ macrocyclic ligand incorporating an oxamido bridge," <i>Inorg. Chem.</i> , 42:1462-1466, 2003.
	C465	Zhao <i>et al.</i> , "Effects of Dextranation on the pharmacokinetics of short peptides. a PET study on mEGF," <i>Bioconjugate Chem.</i> , 10:938-946, 1999.
	C466	Zhou <i>et al.</i> , "Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles," <i>Bioconjugate Chem.</i> , 13:1220-1225, 2002.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

55092434.1

EXAMINER: /Leah Schlientz/

DATE CONSIDERED: 09/28/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.